$772.11▴ 0.46%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$1.08cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
87th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+16.7%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Regeneron Pharmaceuticals, Inc. turns 108¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year. Its valuation sits in the richer end of its own recent range.
Key numbers
Valuation
EPS (TTM)$40.47
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin27.9%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$15.53B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days12 articles
1 bullish2 neutral9 bearish
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
$REGN Securities: Suffer Losses on Your Regeneron Investment? BFA Law Reminds Investors of the Securities Fraud Lawsuit to Recover Losses
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.